ClinTec Expands Executive Leadership Team
News Jan 13, 2016
Dr. Simon is a physician registered in the UK and South Africa with almost 20 years experience in Clinical Medicine and Clinical Research. Prior to joining ClinTec, Dr Simon was an Executive Director of Clinical Research at Merck & Co and spent 14 years in management positions within this leading pharmaceutical company. Dr. Simon will report directly to ClinTec International’s Founder and CEO, Dr. Rabinder Buttar.
Following on from another successful year of growth at ClinTec in 2015, the recruitment of Dr. Simon represents a further strengthening of ClinTec’s Leadership Team and its support for the continued entrepreneurial growth of the organisation.
As CMO and Executive Vice President, Client Relations, Dr. Simon will be responsible for leading and generating value within ClinTec’s strategic partnerships with its pharmaceutical and biotech clients, both in full global programme outsourcing as well as global Functional Outsourcing assignments.
“As we approach the 20th year of continuous global growth and development at ClinTec International, I am proud to enhance our senior leadership team with an enterprising and high calibre industry professional who is already familiar with, and respects, ClinTec’s culture and values which will remain centre stage as we expand our business. Indeed, we are well positioned for the achievement of further global growth for our organisation and I look forward to Dr. Simon playing a key role in ClinTec’s bright future” commented Dr. Rabinder Buttar, ClinTec International’s Founder and CEO.
During his time at Merck, Dr. Simon served as Executive Director of Clinical Research and was responsible for the Eastern European, Middle East and Africa (EEMEA) and Asia Pacific (AP) Regions. This role included developing an overall strategy for the regions, as well as building and maintaining relationships with both internal and external stakeholders. He was responsible for directly supervising and leading a management team comprised of country and sub-regional leaders, Regional Operations Directors and Regional Support Managers, as well as a team of over 400 diverse employees across more than 16 countries.
“I am very excited at the prospect of joining ClinTec International. I have been interacting with this dynamic company for almost 10 years and have been extremely impressed by its innovative approach, flexibility, customer-centricity and professionalism”, remarked Dr. Simon. “ClinTec’s organic growth over the last decade has been remarkable, and I look forward to being part of the ongoing expansion in this challenging new role”, he added.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019